Immunoclin Corporation (IMCL) – Press Releases
-
Spotlight Innovation Commences Part 2 of Phase I Cancer Trial
-
After Successful Formulation Work, Cannabis Science Follows Through With a Full Clinical Drug Development Agreement With ImmunoClin to Deliver GMP Quality Pre-Clinical Data to Enter CS-NEURO-1 Into a
-
Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Crotoxin Clinical Study
-
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
-
Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom
-
ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK
Back to IMCL Stock Lookup